INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of “Hold” by Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned an average recommendation of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $18.00.

Several equities analysts have weighed in on INMB shares. Weiss Ratings restated a “sell (e+)” rating on shares of INmune Bio in a report on Wednesday, October 8th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research note on Sunday, November 9th.

INmune Bio Stock Performance

Shares of INMB opened at $1.65 on Friday. The firm has a market cap of $43.87 million, a PE ratio of -0.78 and a beta of 0.95. INmune Bio has a twelve month low of $1.38 and a twelve month high of $11.64. The firm’s 50 day moving average price is $1.79 and its 200 day moving average price is $3.36.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.07. On average, sell-side analysts anticipate that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd lifted its position in INmune Bio by 240.9% during the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after acquiring an additional 88,928 shares during the last quarter. Westside Investment Management Inc. increased its stake in shares of INmune Bio by 384.0% in the third quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock worth $214,000 after purchasing an additional 82,075 shares during the period. JPMorgan Chase & Co. lifted its position in shares of INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after purchasing an additional 66,700 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of INmune Bio during the 2nd quarter worth about $87,000. Finally, Focus Partners Advisor Solutions LLC grew its holdings in INmune Bio by 321.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock valued at $113,000 after buying an additional 37,224 shares during the last quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.